Dyne Therapeutics to offer 10.3 million shares in IPO priced at $16 to $18 each

/ / News

Dyne Therapeutics, a developer of therapies for muscle diseases, set terms for its initial public offering on Thursday, with plans to offer 10.3 million shares, priced at $16 to $18 each. The company has applied to list on Nasdaq, under the ticker “DYN.” J.P. Morgan, Jefferies, Piper Sandler and Stifel are underwriting the deal. Proceeds will be used to finance R&D, to develop the company’s proprietary FORCE platform and for general corporate purposes. “We are building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases,” the company says in its prospectus. “We are utilizing our proprietary FORCE platform to overcome the current limitations of muscle tissue delivery and advance modern oligonucleotide therapeutics for muscle diseases.”
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.